Know Cancer

forgot password

Allogeneic,Unrelated, Menstrual Derived, Mesenchymal Stem Cell-Like, Endometrial Cells; Administered Intramuscular

Phase 1/Phase 2
18 Years
Not Enrolling
Peripheral Vascular Diseases

Thank you

Trial Information

Allogeneic,Unrelated, Menstrual Derived, Mesenchymal Stem Cell-Like, Endometrial Cells; Administered Intramuscular

The purpose of the trial is to determine safety of intramuscularly derived menstrual
mesenchymal stem cells (otherwise known as Endometrial Regenerative Cells, or ERC) in
patients with critical limb ischemia ineligible for revascularization. Safety will be
defined as freedom from treatment associated adverse events. Efficacy parameters will
comprise endpoints of changes in ankle-brachial index, toe-brachial index, TcPO2, ulcer
healing, rest pain, quality of life, and reduction in amputation.

Patients will receive 25, 50, or 100 million menstrual derived mesenchymal stem cells
(Endometrial Regenerative Cells: ERC) in ten injections of 2.5, 5, or 10 million mesenchymal
stem cells suspended in a volume of 1 ml per injection. Injections will be spaced at least
2 centimeters apart from each other in the gastrocnemius muscle above the failed vascular
perfusion area.

Inclusion Criteria:

1. Non-pregnant patients with critical limb ischemia, Rutherford IV-V, manifested as
rest pain or tissue loss, or with disabling claudication, manifested as exercise
induced thigh or calf pain that impairs activities of daily living, who are not
candidates for surgical bypass or angioplasty due to unfavorable arterial anatomy or
absence of adequate autogenous vein for a below-knee bypass.

2. Patients over 18 years of age with an expected survival of more than one year after

3. Unreconstructable arterial disease will be determined by a vascular surgeon who is
not participating in the study. Unreconstructable arterial disease is defined by
atherocclusive lesions within the arterial tree of the extremity that due to extent
or morphology are not amenable to surgical bypass or PTCA and stenting.

4. Patients with a maximum of 3 non-healing 'flat' surface or 'transdermal' ulcers
Grades 1-2, no ulcer bigger than 2 centimeters (2)

5. Patients with unfavorable anatomy or who are medically unfit to undergo bypass as
determined by a vascular surgeon who is not participating in the study.

6. Vascular imaging (eg angiogram or MRA) to determine vascular anatomy must be
conducted within 3 months of study entry.

7. Patients with low/absent perfusion in the area at or below the gastrocnemius muscle

8. Objective evidence of severe peripheral arterial disease will include an ankle
brachial index (ABI) of less than 0.55, and/or a resting toe brachial index (TBI) of
less than 40.

9. Patients must be competent to give consent.

10. No history of malignant disease except for nonmelanoma skin cancer, no suspicious
findings on chest x-ray, mammography (women over age 35) , Papanicolaou smear (women
over age 40), a normal fecal occult blood (over age 50) and a normal prostate
specific antigen (men over age 45).

11. Patients must have a prothrombin Time (PT) between 12-14 seconds, a partial
thromboplastin time (PTT) of 18-28 seconds, and platelet count >100,000/microliter

12. Patients must have white blood cell count (4.1-10.9x10(3) cells/┬ÁL)

13. Normal liver function tests (AST 8 - 20 U/L, ALT 8 - 20 U/L, and total bilirubin 0.1
- 1.0 mg/dL)

14. Patients must be male or post menopausal women.

Exclusion Criteria:

1. Patients with evidence of active proliferative retinopathy.

2. Patients with poorly controlled diabetes mellitus (HbA1C > 8.5%).

3. Patients with renal insufficiency (Creatinine > 2.5) or failure.

4. Infection as evidenced by WBC count of >15,000 k/cumm and/or temperature >38C.

5. Cellulitis in the afflicted limb that in the opinion of the investigators would
require the use of antibiotics or evidence of osteomyelitis corroborated by
radiographic or scintigraphic examination.

6. Pregnant women (women capable of childbearing must have a negative pregnancy test)

7. Cognitively impaired adult

8. Lower extremity venous disease with pitting edema.

9. History of organ transplant.

10. Patients with ulcer exudates, dry gangrene or exposed bone.

11. Allergies to beta-lactam antibiotics, amphotericin B, or streptomycin

12. Cardiovascular conditions:

- Exercise limiting angina (Canadian Cardiovascular Society Class > 3

- Congestive heart failure (New York Heart Association class > 3

- Unstable angina

- Acute ST elevation myocardial infarction (MI) within 1month

- Transient ischemic attack or stroke within 1 month

- Severe valvular disease

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Description:

Adverse and serious events recorded

Outcome Time Frame:

52 weeks

Safety Issue:


Principal Investigator

Michael P Murphy, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Indiana University


United States: Food and Drug Administration

Study ID:




Start Date:

May 2012

Completion Date:

July 2013

Related Keywords:

  • Peripheral Vascular Diseases
  • critical limb ischemia
  • Vascular Diseases
  • Peripheral Vascular Diseases
  • Peripheral Arterial Disease
  • Adenoma



Indiana University School of MedicineIndianapolis, Indiana  46204